[at Motley Fool] – Gilead Sciences and Johnson & Johnson are about to launch new oral hepatitis C treatments that will significantly reduce Vertex sales from Incivek. The company hopes drugs treating cystic . . . → Read More: Stock Update: Gilead Sciences Inc. (NASDAQ:GILD) – Can Vertex Survive Post-Incivek? Similar posts: Gilead Sciences Inc. (NASDAQ:GILD) – Gilead’s Hepatitis C Pill Works Better, FDA Report Says [at Bloomberg] – Gilead Sciences Inc.’s experimental hepatitis C... Surface RT recovery image released to fix Windows RT 8.1 update issues – Microsoft Corporation (NYSE:MSFT) [at The Verge] – Microsoft is releasing a Surface... Amazon.com Inc. (NASDAQ:AMZN) – Publishers need to know their readers to survive in digital era [Reuters] - Publishers need to get to know their readers...